Clinical Observation of Carteolol Hydrochloride Eye Drops Combined with Travoprost Eye Drops in the Treatment of Open-Angle Glaucoma

Objective: To analyze the therapeutic effects of carteolol hydrochloride (CAR) eye drops combined with travoprost (TRA) eye drops in the treatment of open-angle glaucoma (OAG). Methods: A total of 72 OAG patients (87 eyes) hospitalized between October 2020 and October 2023 were randomly divided into two groups. The combination group received CAR and TRA eye drops, while the control group received CAR eye drops alone. Treatment outcomes were compared in terms of total efficacy rate, visual acuity, intraocular pressure, visual function indicators, hemodynamic parameters, and ocular surface damage indicators. Results: The combination group showed a higher total efficacy rate compared to the control group. After 3 months of treatment, the combination group had better visual acuity, lower intraocular pressure, higher mean sensitivity, lower mean defect, lower resistance index, and higher end-diastolic velocity and peak systolic velocity compared to the control group (P < 0.05). Additionally, the combination group exhibited higher corneal fluorescein staining scores, shorter tear breakup time, and lower Schirmer tear test values compared to the control group (P < 0.05). Conclusion: The combination of CAR and TRA eye drops improves visual acuity, effectively reduces intraocular pressure, enhances visual function, regulates ocular hemodynamics, and mitigates ocular surface damage in OAG patients, demonstrating superior therapeutic efficacy.